期刊文献+

Hepatoprotective effect of silymarin 被引量:13

Hepatoprotective effect of silymarin
在线阅读 下载PDF
导出
摘要 The use of medicinal plants in treating illnesses has been reported since ancestral times.In the case of hepatic diseases,several species such as Silybum marianum,Phyllanthus niruri,and Panus giganteus(Berk.)have been shown to ameliorate hepatic lesions.Silymarin is a natural compound derived from the species Silybum marianum,which is commonly known as Milk thistle.This plant contains at least seven flavoligands and the flavonoid taxifolin.The hepatoprotective and antioxidant activity of silymarin is caused by its ability to inhibit the free radicals that are produced from the metabolism of toxic substances such as ethanol,acetaminophen,and carbon tetrachloride.The generation of free radicals is known to damage cellular membranes and cause lipoperoxidation.Silymarin enhances hepatic glutathione and may contribute to the antioxidant defense of the liver.It has also been shown that silymarin increases protein synthesis in hepatocytes by stimulating RNA polymerase I activity.A previous study on humans reported that silymarin treatment caused a slight increase in the survival of patients with cirrhotic alcoholism compared with untreated controls. The use of medicinal plants in treating illnesses has been reported since ancestral times.In the case of hepatic diseases,several species such as Silybum marianum,Phyllanthus niruri,and Panus giganteus(Berk.)have been shown to ameliorate hepatic lesions.Silymarin is a natural compound derived from the species Silybum marianum,which is commonly known as Milk thistle.This plant contains at least seven flavoligands and the flavonoid taxifolin.The hepatoprotective and antioxidant activity of silymarin is caused by its ability to inhibit the free radicals that are produced from the metabolism of toxic substances such as ethanol,acetaminophen,and carbon tetrachloride.The generation of free radicals is known to damage cellular membranes and cause lipoperoxidation.Silymarin enhances hepatic glutathione and may contribute to the antioxidant defense of the liver.It has also been shown that silymarin increases protein synthesis in hepatocytes by stimulating RNA polymerase I activity.A previous study on humans reported that silymarin treatment caused a slight increase in the survival of patients with cirrhotic alcoholism compared with untreated controls.
出处 《World Journal of Hepatology》 CAS 2014年第3期144-149,共6页 世界肝病学杂志(英文版)(电子版)
基金 Supported by Proyecto SIP 20140856,ESM-IPN
关键词 Silybum marianum Hepatoprotector LIPOPEROXIDATION SILYMARIN Silybum marianum Hepatoprotector Lipoperoxidation Silymarin
  • 相关文献

参考文献17

  • 1Fulvio Cacciapuoti,Anna Scognamiglio,Rossella Palumbo,Raffaele Forte,Federico Cacciapuoti.Silymarin in non alcoholic fatty liver disease[J].World Journal of Hepatology,2013,5(3):109-113. 被引量:18
  • 2Carmela Loguercio,Davide Festi.Silybin and the liver: From basic research to clinical practice[J].World Journal of Gastroenterology,2011,17(18):2288-2301. 被引量:26
  • 3P. A. Abhilash,R. Harikrishnan,M. Indira.Ascorbic acid is superior to silymarin in the recovery of ethanol-induced inflammatory reactions in hepatocytes of guinea pigs[J]. Journal of Physiology and Biochemistry . 2013 (4)
  • 4Do Kwon,Young Jung,Sun Kim,Young Kim,Dal Choi,Young Kim.Alterations in Sulfur Amino Acid Metabolism in Mice Treated withSilymarin: A Novel Mechanism of Its Action Involved in Enhancement of theAntioxidant Defense in Liver[J]. Planta Med . 2013
  • 5Mi Na Kim,Beom Kyung Kim,Kwang-Hyub Han.Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia–Pacific region[J]. Journal of Gastroenterology . 2013 (6)
  • 6Subir Kumar Das,Sukhes Mukherjee.Biochemical and immunological basis of silymarin effect, a milk thistle ( Silybum marianum ) against ethanol-induced oxidative damage[J]. Toxicology Mechanisms and Methods . 2012 (5)
  • 7Wei-Lun Wong,Mahmood Ameen Abdulla,Kek-Heng Chua,Umah Rani Kuppusamy,Yee-Shin Tan,Vikineswary Sabaratnam,Wagner Vilegas.Hepatoprotective Effects of Panus giganteus (Berk.) Corner against Thioacetamide- (TAA-) Induced Liver Injury in Rats[J]. Evidence-Based Complementary and Alternative Medicine . 2012
  • 8Bin Gao,Ramon Bataller.Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets[J]. Gastroenterology . 2011 (5)
  • 9Roy L. Hawke,Sarah J. Schrieber,Tedi A. Soule,Zhiming Wen,Philip C. Smith,Rajender K. Reddy,Abdus S. Wahed,Steven H. Belle,Nezam H. Afdhal,Victor J. Navarro,Josh Berman,Qi-Ying Liu,Edward Doo,Michael W. Fried.Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C[J]. Journal of Clinical Pharmacology . 2010 (4)
  • 10Arlene Sy-Cordero,Tyler Graf,Yuka Nakanishi,Mansukh Wani,Rajesh Agarwal,David Kroll,Nicholas Oberlies.Large-Scale Isolation of Flavonolignans from Silybum marianum Extract Affords New Minor Constituents and Preliminary Structure-Activity Relationships[J]. Planta Med . 2010 (06)

二级参考文献46

  • 1John J Lah.Effects and mechanisms of silibinin on human hepatoma cell lines[J].World Journal of Gastroenterology,2007,13(40):5299-5305. 被引量:12
  • 2Angulo P.Nonalcoholic fatty liver diseaseNew England Journal of Homeopathy,2002.
  • 3Flora K;Hahn M;Rosen H;Benner K.Milk thistle (Silybum marianum) for the therapy of liver disease,1998.
  • 4Clark JM,Brancati FL,Diehl AM.Nonalcoholic Fatty Liver Disease. Gastroenterology . 2002
  • 5Marchesini G,Brizi M,Morselli-Labate AM,et al.Association of nonalcoholic fatty liver disease with insulin resistance. American Journal of Medicine . 1999
  • 6D. R. Matthews,J. P. Hosker,A. S. Rudenski,B. A. Naylor,D. F. Treacher,R. C. Turner.Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man[J]. Diabetologia . 1985 (7)
  • 7Knegelmas M,Hill DB,Vivian B,et al.Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology . 2003
  • 8Nair S,Diehl AM,Wiseman M,et al.Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Alimentary Pharmacology and Therapeutics . 2004
  • 9Dixon JB,Bhathal PS,O’Brien PE.Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology . 2001
  • 10Sanyal AJ.AGA technical review on nonalcoholic fatty liver disease. Gastroenterology . 2002

共引文献42

同被引文献41

引证文献13

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部